Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Buy Rating Affirmed for Merus With Increased Price Objective Amid Promising Peto' Efficacy and Market Potential
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Royalty Pharma (RPRX)
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating
Merus Analyst Ratings
Truist Financial Sticks to Its Buy Rating for Merus (MRUS)
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities
Merus (MRUS) Receives a Buy From TD Cowen
Truist Financial Keeps Their Buy Rating on Merus (MRUS)
Merus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and Immunocore Holdings (IMCR)
Merus (MRUS) Initiated With a Buy at Truist Financial
Bank of America Securities Remains a Buy on Merus (MRUS)
Buy Rating on Merus Stock Amid Anticipation of Positive Clinical Trial Results and Growing Investor Interest
Merus Analyst Ratings
Merus Analyst Ratings
Buy Rating Affirmed for Merus on Promising HNSCC Clinical Data and Competitive Outlook
Analysts Have Conflicting Sentiments on These Healthcare Companies: ZimVie Inc (ZIMV) and Merus (MRUS)
Merus Analyst Ratings
Merus Analyst Ratings
No Data